Kymera Therapeutics Inc (KYMR) cash flow statement

NASDAQ · Health Care

$121.52 -3.44% Close Nov 17, 2026 Live

TrendArc score 39 of 100 · Health 1.1 · Momentum 7.2 · Moat 4.5 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

-$234 million

against -$207 million the year before

In the fiscal year to December 2025, Kymera Therapeutics used $233 million in its operations and spent $1 million on capital spending, a free cash flow of -$234 million. That was -597.6% of revenue, against -440.5% the year before. Over the last four quarters, to September 30, 2026, it was -$289 million.

Free cash flow and net income, the last 8 fiscal years

-$400M-$300M-$200M-$100M$100M$200M$300M$400M20182019202020212022202320242025-$19.2MFree cash flow -$234MNet income -$311M-$400M-$300M-$200M-$100M$100M$200M$300M$400M2019202120232025Free cash flow -$234MNet income -$311M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Cash flow statement, the last 8 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating activities
Net income-311-224-147-155-100-46-41-21
Depreciation and amortisation87432210
Stock-based pay686055433525511
Working capital and other items10-33-3-37-56127573
Cash from operations-288-233-195-103-153-1298818-18
Investing activities
Capital spending-1-1-13-34-3-2-9-1-1
Businesses bought and sold, net00000000
Investments bought and sold, net-520-39117423-98-413-160
Cash from investing-521-40414021-100-423-16-1
Financing activities
Debt issued or repaid, net-1-20-1-1-100
Shares issued less bought back966992610415425119700
Dividends paid000000000
Other financing00000933553
Cash from financing99160941532502893553
Net change in cash23710412021-453634
Free cash flow
Free cash flow-289-234-207-137-156-1317917-19
Free cash flow margin-282.6%-597.6%-440.5%-174.7%-333.0%-179.2%232.2%592.1%—
Free cash flow per share-$2.77-$2.76-$2.35-$2.89-$2.72$4.56$10.23-$10.25
Free cash flow less stock-based pay-294-262-180-191-1567416-20

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Kymera Therapeutics against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
InsuletPODD Dec 2025$350M12.9%
DaVitaDVA Dec 2025$1.31B9.6%
Ensign GroupENSG Dec 2025$371M7.3%
Universal Health ServicesUHS Dec 2025$825M4.7%
Henry ScheinHSIC Dec 2025$521M4.0%
Kymera TherapeuticsKYMR Dec 2025-$234M-597.6%
Peer median7.3%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Kymera Therapeutics with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Kymera Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.